FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients

Key Takeaways NVO won accelerated FDA nod for Wegovy HD 7.2 mg for obesity patients, targeting an April 2026 launch.STEP UP data showed 20.7% weight loss at 72 weeks with 7.2 mg vs 17.5% for 2.4 mg and 2.4% for placebo.About one-third on Wegovy 7.2 mg lost at least 25% weight. Safety and tolerability matched the 2.4 mg profile.Novo Nordisk (NVO) announced that the FDA has approved Wegovy HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction in the long ter ...